CompletedPhase 3Phase 4ACTRN12608000447358

Pravastatin in Polycystic Kidney Disease

Effect of Pravastatin on Kidney Function in Polycystic Kidney Disease

Sponsor

Clifford Craig Medical Research Trust

Enrollment

100 participants

Start Date

Jan 1, 1998

Study Type

Interventional

Conditions

Polycystic Kidney Disease

Summary

Polycystic kidney disease is a common cause of kidney failure Statins may slow kidney disease progression. This study aimed to assess whether pravastatin 20mg could slow the progression of kidney disease

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This trial tests whether the cholesterol-lowering drug pravastatin can slow the progression of polycystic kidney disease (PKD). It is for adults aged 18-85 who have been diagnosed with PKD. Participants will take either pravastatin or a placebo and be monitored to see if the medication helps protect kidney function.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Pravastatin 20mg orally daily for 2 years

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000447358

Related Trials

Pravastatin in Polycystic Kidney Disease

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(1)

Related Trials

Early PKD Observational Cohort Study

Polycystic Kidney Disease Data Repository

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

PKD Clinical and Translational Core Study

Amnioinfusion for Fetal Renal Failure